Managing Pharmacokinetic Variability in Anti-Tuberculosis Treatment

Initial Assessment and Risk Stratification

The American Thoracic Society recommends calculating actual creatinine clearance using 24-hour urine collection rather than relying on serum creatinine alone, especially in elderly patients or those with reduced muscle mass, as serum creatinine can be misleading and underestimate the degree of renal impairment 2
Baseline measurements, including renal function, liver function tests, visual acuity testing, audiogram, and vestibular testing, should be established before initiating therapy, as this baseline is critical for monitoring drug-related toxicity during treatment 3

The Centers for Disease Control and Prevention recommends using standard dosing of 300 mg once daily or 900 mg three times weekly for Isoniazid (INH), as it is hepatically metabolized and not significantly affected by renal impairment 1, 2
The Centers for Disease Control and Prevention recommends using standard dosing of 600 mg once daily or 600 mg three times weekly for Rifampin (RIF), as it undergoes hepatic metabolism 1, 2
For Pyrazinamide (PZA), the American Thoracic Society recommends using 25-35 mg/kg three times weekly (NOT daily) in patients with CrCl <30 mL/min, as PZA metabolites accumulate in renal insufficiency 2, 4
For Ethambutol (EMB), the American Thoracic Society recommends using 20-25 mg/kg three times weekly (NOT daily), as approximately 80% undergoes renal clearance and will accumulate with daily dosing 2, 4

The American Thoracic Society recommends considering regimens with fewer hepatotoxic agents for patients with unstable or advanced liver disease, and obtaining expert consultation, as isoniazid, rifampin, and pyrazinamide are the primary hepatotoxic drugs 1
The American Thoracic Society recommends monitoring liver function tests closely, recognizing that tuberculosis itself may involve the liver and cause abnormal function that improves with effective treatment 1

The Centers for Disease Control and Prevention recommends measuring serum drug concentrations in all patients with renal or hepatic impairment, as well as those with slow response to treatment, drug-resistant tuberculosis, HIV co-infection with multiple interacting medications, or malabsorption syndromes 1, 2
The American Thoracic Society recommends collecting blood samples at 2 hours post-dose as the primary time point, as this captures peak concentrations (Cmax) for isoniazid, rifampin, pyrazinamide, and ethambutol 1, 2

The American Thoracic Society recommends reviewing all concomitant medications systematically, as patients with end-stage renal disease or HIV often take multiple medications that interact with anti-TB drugs 1, 2
The American Thoracic Society recommends using therapeutic drug monitoring (TDM) as the decisive tool for sorting out complex multi-drug interactions and determining the necessary doses patients require 1, 2

The American Thoracic Society recommends never simply reducing doses to compensate for renal impairment, as this lowers peak concentrations and compromises efficacy through reduced concentration-dependent killing 2, 7
The American Thoracic Society recommends not assuming "normal" serum creatinine indicates adequate renal function in elderly patients, those with low muscle mass, or patients on CRRT, as muscle mass decline can mask severe renal impairment 2, 7